Mendus

• The financing commitments will allow the Company to reach its next clinical read-outs from the ongoing ADVANCE II and ALISON trials, to prepare for next clinical trials and to establish pivotal-stage and commercial manufacturing for its lead program DCP-001
• Mendus has signed a commitment letter with Van Herk Investments for a shareholder loan up to SEK 50 million
• Negma has committed to provide up to SEK 200 million in convertible bonds. Financing is available in tranches of up to SEK 10 million over a period of 30 months following closing of the Transaction
• Following the financial advisor role in the merger between DC Prime and Mendus (former Immunicum) in December 2020 and as Joint Global Coordinator in the Accelerated Bookbuild Offering in June 2021, Kempen & Co is proud to have assisted Mendus as a repeat client
• In difficult market circumstances, Kempen & Co has been able to assist its client with an innovative financing solution. This transaction underpins our ambition to serve our clients with a wide variety of tailormade financing structures

• Mendus AB is a biopharmaceutical company developing off-the-shelf immune primers based on allogeneic dendritic cell biology to treat blood-borne and solid tumors. The company addresses key challenges in cancer therapy being difficult-to-treat tumors and tumors with a high risk of recurrence through unique approaches of intratumoral priming and cancer relapse vaccination

In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

• Joint Global Coordinator in BioInvent’s in the SEK 299 million directed share issue
• Sole Global Coordinator in the SEK 200m financing consisting of a SEK 150m PIPE and a SEK 50m Fully Guaranteed Rights Issue by Abliva
• Joint Global Coordinator & Joint Bookrunner in the SEK 150 million Fully Guaranteed Rights Issue by SynAct Pharma
• Co-Manager in the USD 700 million Capital Increase by Argenx
• Sole Block Placing Agent in the placement of 1.4m Molecular Partners shares
• Joint Bookrunner in the USD 127 million Nasdaq IPO of Forbion European Acquisition Corp
• Co-Lead Manager in the USD 115 million Nasdaq Initial Public Offering by IO Biotech
• Lead manager in the USD 127 million Global Offering of Merus
• Joint Global Coordinator and Joint Bookrunner in the €31.5 million Euronext IPO by MaaT Pharma
• Co-Manager in the USD 460 million Capital Increase by Ascendis Pharma
• Joint Bookrunner in the SEK 324 million Capital Increase by Calliditas Therapeutics